Mesoblast (NASDAQ:MESO - Get Free Report) is anticipated to post its quarterly earnings results on Thursday, February 27th. Analysts expect Mesoblast to post earnings of ($0.25) per share and revenue of $2.39 million for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.
MESO opened at $17.42 on Thursday. The company has a fifty day moving average price of $17.59 and a 200-day moving average price of $11.65. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. Mesoblast has a one year low of $1.91 and a one year high of $22.00.
A number of analysts have recently issued reports on the stock. Cantor Fitzgerald raised shares of Mesoblast to a "strong-buy" rating in a report on Thursday, January 30th. Piper Sandler reaffirmed an "overweight" rating and set a $24.00 price objective (up from $15.00) on shares of Mesoblast in a report on Friday, February 7th. Finally, Jefferies Financial Group downgraded shares of Mesoblast from a "buy" rating to a "hold" rating in a report on Monday, December 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $18.00.
Read Our Latest Stock Analysis on Mesoblast
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.